CRISPR/Cas9 Screening Data from Oxaliplatin-Treated Tumors

A 4.8 GB dataset from a CRISPR/Cas9 screening experiment on tumors treated with oxaliplatin. The data was generated by author Hui-Fang Hu, with sequencing performed on an Illumina NovaSeq 6000 platform. It was last updated on April 20, 2026.

Use Cases

• Identify genes conferring resistance to oxaliplatin based on sgRNA abundance changes.
• Validate CRISPR screening protocols using the described PCR and library preparation methods.
• Benchmark analysis pipelines for next-generation sequencing data from pooled genetic screens.

Strengths

• Data size is 4.8 GB, indicating substantial sequencing depth.
• Experimental protocol is described in detail, including drug dosage (20 mg/kg oxaliplatin) and sequencing platform (Illumina NovaSeq 6000).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

Hui-Fang Hu via figshare

Collection Method

CRISPR/Cas9 screening on oxaliplatin-treated and control tumors, with sgRNA amplification and Illumina sequencing.

Freshness

Last updated 2026-04-20 09:21:15; freshness should be verified.

Geography

Sequencing performed by Genedenovo Biotechnology Co., Ltd. in Guangzhou, China.